Faropenem Sodium 300 mg Extended Release
Faropenem Sodium 300mg Extended Release — same oral penem mechanism as FAROFLY™ 200 (PBP binding, cell wall synthesis inhibition, ESBL stability, broad aerobic-anaerobic spectrum). The ER formulation releases faropenem over an extended period, achieving more sustained plasma concentrations that maintain drug levels above the MIC for a greater portion of the dosing interval. This pharmacokinetic optimisation is particularly important for beta-lactam antibiotics like faropenem, which exhibit time-dependent killing — the primary determinant of efficacy is the percentage of time plasma drug concentrations exceed the MIC, not peak concentration.
Same indications as FAROFLY™ 200 but for moderate-to-severe infections or cases requiring the higher 300mg dose and extended-release pharmacokinetics: severe pneumonia, complicated UTI with ESBL, deep-seated skin and soft tissue infections, and high-inoculum resistant organism infections where maintaining drug concentrations above the MIC throughout the dosing interval is critical.
Dosage and administration should be as prescribed by a qualified doctor or medical professional. Do not self-medicate. Always follow your physician's instructions regarding dose, frequency and duration of treatment.
FAROFLY™ 300 ER completes the faropenem range alongside FAROFLY™ 200, providing prescribers a dose escalation option within the same brand for cases requiring higher faropenem exposure. The extended-release formulation also improves compliance — twice daily is more reliably completed than three times daily for a 14-day course, particularly important for resistant infections where premature discontinuation risks clinical failure and resistance amplification.
Disclaimer: To be used under medical supervision only. Not intended for general public promotion. This content is meant for registered healthcare professionals only.